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Purpose: To evaluate whether dexamethasone injected intracamerally at the conclusion of 
surgery can safely and effectively reduce postoperative inflammation and improve surgical 
outcomes in eyes with and without glaucoma.
Methods: Retrospective chart review of 176 consecutive eyes from 146 patients receiving 
uncomplicated phacoemulsification (PE) (n = 118 total, 82 with glaucoma), glaucoma 
drainage device (GDD) (n = 35), combined PE/GDD (n = 11) and combined PE/endoscopic 
cyclophotocoagulation (n = 12). Ninety-one eyes from 76 patients were injected with 0.4 mg 
dexamethasone intracamerally at the conclusion of surgery. All eyes received standard 
postoperative prednisolone and ketorolac eyedrops. Outcomes were measured for four to eight 
weeks by subjective complaints, visual acuity (VA), slit-lamp biomicroscopy, intraocular 
pressure (IOP) and postoperative complications.
Results: Dexamethasone significantly reduced the odds of having an increased anterior 
chamber (AC) cell score after PE (p = 0.0013). Mean AC cell score ± SD in nonglaucomatous 
eyes was 1.3 ± 0.8 in control and 0.8 ± 0.7 with dexamethasone; scores in glaucomatous eyes 
were 1.3 ± 0.7 in control and 0.9 ± 0.8 with dexamethasone. Treated nonglaucomatous eyes 
had significantly fewer subjective complaints after PE (22.2% vs 64.7% in control; p = 0.0083). 
Dexamethasone had no significant effects on VA, corneal changes, IOP one day and one month 
after surgery, or long-term complications.
Conclusions: Intracameral dexamethasone given at the end of cataract surgery significantly 
reduces postoperative AC cells in eyes with and without glaucoma, and improves subjective 
reports of recovery in nonglaucomatous eyes. There were no statistically significant risks of 
IOP elevation or other complications in glaucomatous eyes.
Keywords: cataract surgery, glaucoma, steroid, dexamethasone, inflammation, intraocular 
pressure
Introduction
Inflammation after intraocular surgery can prolong patient recovery, raise intraocular 
pressure (IOP), and increase the likelihood of cystoid macular edema (CME), 
synechial formation, posterior capsule opacification (PCO), and secondary glaucoma. 
Recent advances in surgical techniques, surgical tools and intraocular lens (IOL) 
engineering have reduced the amount of inflammation after cataract extraction.1,2 
Current peri-operative pharmacologic treatment and prophylaxis consists of topical 
non-steroidal anti-inflammatory drugs and corticosteroids.
Patient compliance is of concern in the management of postoperative inflammation 
because multiple eye drops must be taken multiple times per day at regular intervals Clinical Ophthalmology 2009:3 346
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over the course of weeks.3 Poor compliance compromises 
the efficacy of topical drugs, which are further limited by 
corneal absorption and have highly variable intraocular 
concentrations during the therapeutic course.4,5 Therefore, 
the opportunity exists to improve management of postopera-
tive inflammation.
Recent reports describe the efficacy of alternate forms 
of steroid delivery in reducing inflammation after cataract 
surgery in otherwise healthy eyes. A single posterior sub-
Tenon’s capsule injection of triamcinolone acetonide (TA) 
at the end of phacoemulsification (PE) has been shown to 
be as effective as steroid eye drops in reducing signs and 
symptoms of postoperative inflammation.6,7 Additionally, 
TA injected intracamerally had anti-inflammatory properties 
equivalent to prednisolone eye drops after cataract surgery.8 
Wadwood and colleagues9 described an anterior segment 
implant that delivers dexamethasone over seven days and 
reduces post-PE inflammation comparably to dexametha-
sone eye drops. Intracameral and intravitreal injections of 
TA given at the end of PE, in conjunction with standard 
postoperative corticosteroid eye drops, have proven to be 
beneficial in uveitic eyes.10–12 Betamethasone injected sub-
conjunctivally at the end of cataract surgery was also shown 
to significantly reduce anterior segment inflammation on the 
first postoperative day, especially in eyes with prior intra-
ocular inflammation.13
Previous studies have largely focused on reducing inflam-
mation after PE in healthy eyes, excluding the glaucomatous 
population in which inflammation and steroid use are of 
particular concern. Tight regulation of postoperative IOP is 
important in these eyes with optic nerve fibers at increased 
risk for injury. Excessive fibrin and synechial formation can 
further compromise aqueous outflow and proper functioning 
of surgical therapies for glaucoma such as tube-shunts. It 
is therefore important to investigate new methods to safely 
reduce postoperative inflammation in glaucomatous eyes. 
Here, we investigated whether an adjunct intracameral injec-
tion of 0.4 mg dexamethasone at the conclusion of surgery 
can safely and effectively reduce postoperative inflammation 
and improve surgical outcomes in eyes with and without 
glaucoma.
Patients and methods
We performed a retrospective chart review of  176 consecutive 
eyes from 146 patients receiving uncomplicated ocular 
surgery by the Glaucoma Service at the University of 
Pittsburgh Medical Center (UPMC) Eye Center from August 
2006 through April 2008. The surgical procedures comprising 
this study were (1) PE with IOL implantation, (2) glaucoma 
drainage device (GDD) implantation, (3) combined PE/GDD, 
and (4) combined PE and endoscopic cyclophotocoagulation 
(PE/ECP). All glaucomatous eyes were medically managed 
until the time of surgery. Thirty-six eyes from 31 patients 
receiving cataract surgery did not have glaucoma. All 
remaining eyes were diagnosed with or suspected to have 
glaucoma. Ninety-one consecutive eyes from 76 patients 
received intracameral injection of 0.4 mg dexamethasone at 
the conclusion of surgery. Routine postoperative care was 
provided and IOP-reducing medications were restarted when 
judged necessary during follow-up visits.
surgical technique
All cases were performed under local anesthesia by one of 
four surgeons (LC, MCH, RJN, JSS). Eyes receiving PE 
were dilated with two drops each of cyclopentolate hydro-
chloride 1% and phenylephrine hydrochloride 2.5% given 
10 minutes apart. Eyes also received one drop each of ketoro-
lac tromethamine 0.5% or nepafenac 0.1%, and gatifloxacin 
0.3% or moxifloxacin 0.5% at the surgeon’s discretion. PE 
was performed through a clear corneal incision using a stop-
and-chop technique and cortex was removed using automated 
coaxial irrigation/aspiration (I/A) handpieces. A foldable 
silicone IOL was inserted into the capsular bag except in two 
cases where the lens was placed in the sulcus. Viscoelastic 
was aspirated and the incision was hydrated. Following 
the procedure, all eyes were instilled with one drop each 
of prednisolone acetate 1%, ketorolac tromethamine 0.5% 
or nepafenac 0.1%, and gatifloxacin 0.3% or moxifloxacin 
0.5%. One hundred of 118 eyes also received one drop of 
brimonidine tartrate 0.1%. Medications will henceforth be 
referred to only by active ingredient.
For cases of combined PE/ECP, a second clear corneal 
incision was made after completion of PE and IOL implan-
tation. An Endo Optiks diode laser (Little Silver, NJ, USA) 
equipped with a curved endoscopic probe was placed into the 
ciliary sulcus and the ciliary body was treated with 0.25 W 
continuous exposure time until ciliary processes whitened. 
Viscoelastic was removed using I/A. Prednisolone, ketorolac, 
gatifloxacin, and brimonidine were given postoperatively as 
described for PE.
Among 46 total GDD and PE/GDD surgeries, Baerveldt 
tube-shunts were used in 42 cases and Ahmed tube-shunts 
were used in four cases. PE with IOL implantation was 
performed immediately preceding GDD placement in the 
combined surgeries. A limbal bridle suture was then placed, 
a conjunctival limbal peritomy was performed, Tenon’s Clinical Ophthalmology 2009:3 347
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capsule was dissected, and recti muscles were isolated. 
Baerveldt tubes were ligated and the plate was placed under 
the muscles. The tube tip was pulled through a sclerostomy 
into the anterior chamber (AC). The tube-shunt was them 
sutured to sclera and covered with pericardium and the 
conjunctiva was reapproximated with Tissel fibrin glue. 
Each eye was given one drop prednisolone, gatifloxacin or 
moxifloxacin, atropine 1% and tobramycin/dexamethasone 
0.3%/0.1% ointment after GDD surgery. Additionally, all 
PE/GDD cases received one drop ketorolac or nepafenac; 
nine of 11 cases also received one drop of brimonidine.
Ninety-one consecutive eyes from 76 patients, comprising 
approximately half of each surgical group, were injected with 
0.1 ml of 4 mg/ml dexamethasone through the paracentesis 
site into the AC at the conclusion of surgery. Dexametha-
sone was used in approximately the second half of all eyes, 
reflecting a change in surgical practice.
Postoperative management
All eyes were evaluated by the Glaucoma Service at UPMC 
Eye Center on the first postoperative day. Subsequent 
follow-up typically occurred one month after PE, and at 
one and three weeks after PE/ECP, GDD and PE/GDD 
unless more frequent visits were required. Anti-glaucoma 
medications were restarted when IOP reached or exceeded 
preoperative IOP. Postoperative medication regimen was as 
follows: (1) PE: ketorolac or nepafenac QID for one week, 
gatifloxacin or moxifloxacin QID for one week, prednisolone 
QID for four weeks or with a one drop/week taper over 
four weeks at the surgeon’s discretion; additionally, 100 
of 118 eyes used brimonidine BID for four weeks, (2) 
GDD: gatifloxacin or moxifloxacin QID for one week, pred-
nisolone QID for four weeks or with a one drop/week taper 
over four weeks at the surgeon’s discretion, and atropine 
BID for one week, (3) PE/GDD: ketorolac or nepafenac QID 
for one week, gatifloxacin or moxifloxacin QID for one week, 
prednisolone QID for four weeks or with a one drop/week 
taper over four weeks at the surgeon’s discretion, atropine 
BID for one week; additionally, nine of 11 eyes used brimo-
nidine BID for four weeks, (4) PE/ECP: ketorolac QID for 
one week, gatifloxacin QID for one week, prednisolone QID 
for four weeks and brimonidine BID for four weeks.
Outcome measures
At each clinic visit, outcomes were measured by subjective 
complaints, visual acuity (VA), slit-lamp biomicroscopy and 
IOP measurements by Goldmann applanation tonometry. 
Baseline values were taken from the most recent preoperative 
clinic visit. Subjective complaints were scored as a 0 for no 
complaints or 1 for symptoms of pain, blurry vision, redness, 
foreign body sensation, tearing or photophobia. Postoperative 
VA was measured by Snellen VA chart and scored as 0 for 
unchanged or improved VA from baseline or 1 for worsened 
VA. Corneal changes were scored as 0 or 1 for the presence 
of new microcystic or stromal edema, Descemet’s membrane 
folds (DMF) or keratic precipitates (KP). Aqueous cell 
was graded according to the number of inflammatory cells 
seen in a 1 × 3 mm high-powered beam at full intensity at 
a 45°–60° angle as 0 – trace (5 cells), 1+ (5–10 cells), 2+ 
(10–20 cells), 3+ (20–30 cells) and 4+ (cells too numerous 
to count). No eyes included in this study had greater than 
trace aqueous cell preoperatively. An outcome measure was 
occasionally incomplete in the medical record; however this 
did not preclude the use of an otherwise complete case, and 
the results reflect the missing data accordingly. The devel-
opment of postoperative complications including elevated 
IOP defined as greater than 10 mmHg above baseline, 
pseudophakic CME, choroidal effusions, synechial angle 
closure, hyphema and AC leaks were followed for four to 
eight weeks.
statistical analysis
Data were compiled using Excel 2007 (Microsoft Corpora-
tion, Seattle, WA, USA) and Prism 4 for Windows (GraphPad 
Software Incorporated, La Jolla, CA, USA) and analyzed 
with R 2008 (R Development Core Team, Vienna, Austria). 
Logistic regression was used to analyze postoperative com-
plaints, reduced VA, corneal changes and AC cell scores. 
IOP was analyzed using a generalized estimating equations 
model for PE and a linear mixed effects model for GDD. 
P-values  0.05 were considered significant.
Results
This retrospective chart review of uncomplicated ocular 
surgery outcomes included 140 eyes from 115 patients with 
diagnosed or suspected glaucoma and 36 non-glaucomatous 
eyes from 31 patients. Table 1 shows the number of eyes 
and glaucoma diagnoses represented, with some eyes having 
multiple types of glaucoma. Ninety-one consecutive eyes from 
76 patients received intracameral injection of dexamethasone 
at the conclusion of PE, GDD, PE/GDD, and PE/ECP 
surgeries. No cases with greater than trace aqueous cells 
preoperatively were included in the study, although seven 
eyes had a history of uveitis or uveitic glaucoma. Similarly, 
eyes with greater than trace corneal abnormalities at base-
line were excluded from the study; 10 eyes had coexisting Clinical Ophthalmology 2009:3 348
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corneal disease. Baseline VA and IOP were taken from the 
most recent preoperative clinic visit, which was a mean ± 
SD of 32.9 ± 22.3 days prior to surgery. There were no 
significant differences in mean ages between control and 
treated eyes in each surgical group (Table 2, p-values not 
shown). Small sample sizes for combined surgeries precluded 
meaningful statistical analyses, but the data are included for 
comparison.
Measures of postoperative inflammation
Signs and symptoms of ocular inflammation were measured 
on the first postoperative day (Table 2). Subjective complaints 
of pain, blurry vision, redness, foreign body sensation, tearing 
and photophobia were mild and self-limited in nearly all cases, 
and so were scored in a binary manner. Non-glaucomatous 
eyes treated with dexamethasone after PE had significantly 
fewer reports of postoperative complaints, 22.2% compared 
to 64.7% in untreated eyes (p = 0.0083; Table 2). There was 
no significant difference in incidence of postoperative com-
plaints in glaucomatous eyes treated with dexamethasone, 
36.4% compared to 41.7% in untreated eyes (p = 0.58).
VA was recorded as a binary variable to reflect worsening 
from preoperative baseline because it was impossible to dis-
cern whether VA reduction was secondary to inflammatory 
changes, glaucoma or coexisting retinal disease. There was no 
significant difference in postoperative VA between eyes with 
and without glaucoma (p = 0.85). Glaucomatous eyes treated 
with dexamethasone after PE had lower incidence of reduced 
VA, 14.6% compared to 20.0% in controls, but little effect 
was seen in any other surgical group (Table 2). There was 
no statistically significant effect of dexamethasone on post-
operative VA (PE, p = 0.61; GDD, p = 0.93).
There was no significant difference in corneal changes, 
including edema, DMF or KP, between eyes with and 
without glaucoma on the first postoperative day (p = 0.91). 
Dexamethasone treatment was associated with a lower 
incidence of inflammatory corneal changes after PE (33.3% 
in treated nonglaucomatous eyes vs 47.1% in untreated; 
36.4% in treated glaucomatous eyes vs 47.4% in untreated) 
and GDD (17.7% in treated vs. 27.8% in untreated) (Table 2). 
However, there were insufficient data to conclude a statistically 
significant effect of dexamethasone on postoperative corneal 
changes (PE, p = 0.44; GDD, p = 0.48). None of the 10 eyes 
with coexisting corneal disease developed postoperative 
corneal changes on exam.
There was no significant difference in the quantity of 
aqueous inflammatory cells, scored from 0 to 4+, between 
eyes with and without glaucoma on the first postoperative 
day (p = 0.81). The frequency distribution of AC cell scores 
on the first postoperative day after PE was skewed right in 
the presence of dexamethasone (Figure 1A). Mode AC cell 
score in glaucomatous eyes was 1+ in 52% treated cases and 
2+ in 47% untreated cases. This resulted in a lower mean 
AC cell score ± SD in nonglaucomatous (control 1.3 ± 0.8, 
dexamethasone 0.8 ± 0.7) and glaucomatous eyes (control 1.3 ± 
0.7, dexamethasone 0.9 ± 0.8) treated with dexamethasone 
compared to controls (Table 2; Figure 1B). The odds of 
having an increased AC cell score after PE was significantly 
reduced in eyes treated with dexamethasone (95% confidence 
interval: 0.15, 0.63; p = 0.0013).
Similar but less pronounced effects of dexamethasone on 
AC cell score distribution were seen after GDD (Figure 2), 
PE/GDD (Figure 3) and PE/ECP (Figure 4). A large propor-
tion of eyes receiving GDD surgery had an AC cell score of 
0 (44% of control eyes, 35% of treated eyes). However, the 
frequency distribution of AC cell scores among eyes with a 
score 1+ sloped upward in controls but downward in treated 
eyes (Figure 2). Mean AC cell scores after GDD were not 
statistically significant between dexamethasone-treated eyes 
and control (p = 0.81) (Table 2).
Among the seven eyes with a diagnosis of uveitis or 
uveitic glaucoma, two eyes were untreated and five eyes 
received dexamethasone. Both untreated eyes had an AC 
score of 0. Two treated eyes had scores of 1+ cell and three 
treated eyes had scores of 2+ cell.
iOP and late complications
IOP was measured preoperatively (mean ± SD of 32.9 ± 
22.3 days), on the first postoperative day (POD1) for each 
experimental group, and approximately one month after 
PE (32.4 ± 8.2 days). There was a significant increase 
in estimated IOP (preoperative 15.8 ± 0.9 mmHg) of 
Table 1 Distribution of glaucoma diagnoses
Diagnosis Number of eyes
Primary open angle glaucoma 68
glaucoma suspect 16
Chronic angle closure glaucoma 12
Pseudoexfoliation syndrome 13
neovascular glaucoma 10
Uveitis/uveitic glaucoma 7
normotension glaucoma 7
Congenital/childhood glaucoma 5
steroid-induced glaucoma 5
Pigment dispersion syndrome 4
Total 147Clinical Ophthalmology 2009:3 349
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2.3 ± 0.7 mmHg (p = 0.00065) one day after PE that returned 
to near-baseline levels after one month (p = 0.56), indepen-
dent of treatment group (Table 3). IOP after PE was not 
significantly altered by dexamethasone treatment, regardless 
of time after surgery or diagnosis of glaucoma (p = 0.12). In 
fact, dexamethasone was associated with a small decrease 
of 1.9 ± 1.2 mmHg in IOP rather than a rise in IOP. In glau-
comatous eyes, dexamethasone treatment correlated with an 
overall 0.1 ± 1.6 mmHg increase in estimated IOP compared 
to untreated nonglaucomatous eyes (p = 0.052).
The incidence of eyes with elevated IOP  10 mmHg 
from baseline one day after PE ranged from 4.7%–16.7%, 
corresponding to one to three eyes, in each experimental 
group (Table 4). Paracentesis was performed on one glau-
comatous control eye and one glaucomatous treated eye 
on the first postoperative day. Elevated IOP was otherwise 
self-limited or managed medically. Five treated eyes (11.6%) 
had POD1 IOP within 10 mmHg of baseline but developed 
delayed ocular hypertension (at days 12, 22, 29, 33, and 40) 
and were considered steroid responders; one of these eyes 
had a known history of prior steroid-induced ocular hyper-
tension. In all five cases, IOP returned to preoperative levels 
within two to four weeks after discontinuing topical steroids 
and restarting some or all of the preoperative IOP-lowering 
medications.
No significant difference in estimated IOP (preopera-
tive 31.8 ± 8.7 mmHg) was observed one day after GDD 
(-3.6 ± 3.0 mmHg; p = 0.24) or with dexamethasone treatment 
(3.0 ± 3.8 mmHg; p = 0.44) compared to controls (Table 3). 
Three control eyes and two treated eyes had elevated IOP 
one day after GDD surgery, of which one control eye had 
retained viscoelastic in the AC (Table 4). Steroid-induced 
IOP elevation was thought to occur in two control eyes at 
34 and 64 days postoperatively, and two treated eyes at 22 and 
40 days postoperatively. One of the control eyes had a history 
of previous steroid-response.
Mean IOPs ± SD one day after PE/GDD were compa-
rable between controls (19.0 ± 15.6 mmHg) and treated eyes 
(23.0 ± 24.0 mmHg). One treated eye had elevated IOP after 
PE/GDD resolving after paracentesis; one control eye with 
a history of steroid-response again had steroid-induced IOP 
elevation diagnosed 36 days after PE/GDD (Table 4). After 
PE/ECP, two control eyes (POD1 IOP 30 and 35) and two 
treated eyes (POD1 IOP 40 and 52) had IOP spikes. One 
of the control eyes had elevated IOP secondary to retained 
viscoelastic in the AC. Additionally, one control eye was 
considered a steroid responder 51 days after PE/ECP.
The surgeries and outcomes of the five eyes with 
prior history of steroid-induced ocular hypertension were 
(1) control GDD developed steroid response, (2) control 
PE/GDD developed steroid response, (3) control PE/ECP 
with no complications, (4) dexamethasone-treated PE devel-
oped steroid response, and (5) dexamethasone-treated GDD 
developed synechial angle closure but no steroid response.
Late adverse events related to inflammation were uncom-
mon after any surgery (Table 4). Mild CME was seen on 
fundoscopic exam in one treated eye 33 days after PE, which 
resolved on exam 10 days later without further intervention. 
One treated eye developed choroidal effusions after GDD, one 
control eye developed choroidal effusions after PE/GDD, and 
one treated eye developed synechial angle closure after GDD. 
There were 10 postoperative hyphemas and two AC leaks.
Discussion
This study investigated whether dexamethasone injected 
intracamerally at the conclusion of surgery could safely and 
A B
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 1+ 2+ 3+
AC cell score
%
 
E
y
e
s
** Ctrl − glaucoma (n = 17)
Ctrl + glaucoma (n = 38)
Dexa − glaucoma (n = 17)
Dexa + glaucoma (n = 48)
1.5
0.5
0.0
1.0
M
e
a
n
 
A
C
 
c
e
l
l
 
s
c
o
r
e
Ctrl − glaucoma
Ctrl + glaucoma
Dexa + glaucoma
Dexa − glaucoma
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effectively reduce postoperative inflammation and improve 
surgical outcomes in glaucomatous eyes when used in 
conjunction with standard postoperative medications. We 
found that dexamethasone treatment significantly reduced the 
quantity of aqueous inflammatory cells in glaucomatous and 
control eyes one day after PE (p = 0.0013; Table 2, Figure 1). 
The 95% confidence interval for the odds ratio (0.15, 0.63) 
indicates that even the minimum effect of dexamethasone is 
fairly large in reducing AC cell. Dexamethasone use was also 
associated with significantly fewer subjective complaints of 
discomfort, blurry vision, redness, tearing and photophobia in 
non-glaucomatous eyes (p = 0.0083; Table 2). Postoperative 
comfort showed moderate improvement when dexametha-
sone was given after GDD surgery (p = 0.10). Although not 
statistically significant, there was a trend toward decreased 
incidence of corneal edema, DMF and KP in treated eyes 
(Table 2). Since this study involved primarily glaucomatous 
eyes with varying degrees of visual field defects, VA was 
scored as postoperative reduction from baseline rather than 
improvement from baseline. By our methods, no change in 
postoperative VA reduction was noted in eyes treated with 
dexamethasone (Table 2).
We also demonstrate that intracameral dexamethasone 
can safely be given after surgery in eyes with different 
types of glaucoma with minimal concern for postoperative 
IOP elevations (Tables 1, 3 and 4). In fact, estimated IOP 
decreased by 1.9 ± 1.2 mmHg in dexamethasone treated 
eyes after PE (p = 0.12; Table 3). Paganelli and colleagues7 
reported a similar finding of significantly lower IOP up to 
28 days after PE in eyes receiving posterior sub-Tenon’s 
injection of TA compared to prednisolone eyedrops. 
Dexamethasone in glaucomatous eyes caused almost no 
deviation (0.1 ± 1.6 mmHg) from estimated IOP in untreated 
non-glaucomatous eyes. Additionally, there was a low and 
insignificant incidence of IOP spikes greater than 10 mmHg 
one day after surgery in dexamethasone-treated and glau-
comatous eyes (Table 4). Among eyes with prior history of 
steroid-induced ocular hypertension, two of the three eyes 
that were not given dexamethasone subsequently developed 
a steroid response, and one of the two eyes that were given 
dexamethasone later had a steroid response. Therefore the 
risk of recurrent steroid-induced IOP elevation was not 
increased by intracameral dexamethasone injection. Other 
postoperative complications associated with inflammation 
including CME and synechial angle closure were rare in both 
treated and control eyes (Table 4).
While we show intracameral dexamethasone given in 
conjunction with a standard course of topical corticosteroids 
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Figure 2 Frequency distribution of AC cell scores on the first postoperative day after GDD surgery.
Abbreviations: AC, anterior chamber; Ctrl, control; Dexa, dexamethasone; gDD, glaucoma drainage device.
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Figure 3 Frequency distribution of AC cell scores on the first postoperative day after combined PE/GDD surgery.
Abbreviations: AC, anterior chamber; Ctrl, control; Dexa, dexamethasone; GDD, glaucoma drainage device; PE, phacoemulsification.
improves postoperative inflammation, it is next important 
to determine if the use of concurrent topical corticosteroids 
can be reduced. Unlike topical applications, the intracameral 
route provides drug delivery directly to the site of interest 
during the early events of inflammatory cascade activation. 
Gills and Gills14 were able to replace postoperative steroid 
drops with increasing concentrations of intracameral 
TA injected after cataract surgery. We hypothesize that 
the high relative potency of dexamethasone may confer 
greater efficacy than TA when given as a single injection. Clinical Ophthalmology 2009:3 352
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Rapid aqueous volume turnover and short half-life of 
intraocular dexamethasone, both on the order of several 
hours, would help minimize the risk of steroid-induced 
ocular hypertension and corneal and systemic side effects 
caused by prolonged topical corticosteroid usage.15,16 
Injection through the paracentesis site created during 
surgery also avoids further complications related to sub-
Tenon’s and intravitreal injections including globe rupture, 
central artery occlusion, and choroidal or retinal circulation 
injections.17–20
The sustained duration of action of sub-Tenon’s and 
intravitreal injections of TA may preclude safe use in 
glaucomatous eyes that require strict IOP control.6,7,11,12 
TA is detectable for months after intravitreal injection 
and is reported to increase IOP.21–25 Roth and colleagues 
demonstrated that IOP spikes 20 mmHg occurred signifi-
cantly more often after intravitreal TA injection in eyes with 
prior glaucoma.26 Sub-Tenon’s injection of TA has also been 
reported to cause ocular hypertension that can be resistant 
to maximum medical therapy.27–29 In contrast, intracameral 
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Figure 4 Frequency distribution of AC cell scores on the first postoperative day after combined PE/ECP.
Abbreviations: AC, anterior chamber; Ctrl, control; Dexa, dexamethasone; ECP, endoscopic cyclophotocoagulation; PE, phacoemulsification.
Table 3 Statistical analyses of the effects of dexamethasone on postoperative ∆iOP
Surgery Experimental group GS/Dx glaucoma n Pre-op mean  
IOP ± SEM (mmHg)
POD1 mean  
IOP ± SEM (mmHg)
POM1 mean  
IOP ± SEM (mmHg)
Pe Ctrl n 17 15.2 ± 0.8 19.8 ± 2.0 14.4 ± 0.6
Pe Dexa n 18 14.2 ± 0.8 16.4 ± 1.2 12.5 ± 0.8
Pe Ctrl Y 38 15.2 ± 1.1 17.1 ± 1.1 14.1 ± 0.7
Pe Dexa Y 44 15.1 ± 0.6 17.1 ± 1.1 16.3 ± 1.3
gDD Ctrl Y 16 27.3 ± 2.2 21.2 ± 4.1
gDD Dexa Y 17 28.1 ± 3.3 26.9 ± 3.7
Pe/gDD Ctrl Y 4 23.0 ± 5.4 19.0 ± 9.0
Pe/gDD Dexa Y 7 29.9 ± 5.6 23.0 ± 9.1
Pe/eCP Ctrl Y 7 20.0 ± 3.8 20.0 ± 4.7
Pe/eCP Dexa Y 5 16.8 ± 0.5 28.8 ± 7.7
Abbreviations:  Ctrl, control eye; Dexa, dexamethasone-treated eye; Dx glaucoma, diagnosed glaucoma; eCP, endoscopic cyclophotocoagulation; gDD, glaucoma drainage 
device; gs, glaucoma suspect; iOP, intraocular pressure; Pe, phacoemulsification; POD1, postoperative day 1; POM1, postoperative month 1; Pre-op, preoperative; seM, 
standard error of the mean.Clinical Ophthalmology 2009:3 353
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Table 4 Postoperative complications
Surgery Comparison Estimated ∆IOP ± SE (mmHg) p-value
Pe POD1 vs preoperative 2.3 ± 0.7 0.00065***
Pe POM1 vs preoperative -0.4 ± 0.6 0.56
Pe Dexa vs ctrl -1.9 ± 1.2 0.12
Pe (glauco and dexa) vs (nonglauco and ctrl) 0.1 ± 1.6 0.052
gDD POD1 vs preoperative -3.6 ± 3.0 0.24
gDD Dexa vs ctrl 3.0 ± 3.8 0.44
Abbreviations: Ctrl, control eye; Dexa, dexamethasone-treated eye; glauco, eye with diagnosed or suspected glaucoma; gDD, glaucoma drainage device; iOP, intraocular 
pressure; nonglauco, nonglaucomatous eye; Pe, phacoemulsification; POD1, postoperative day 1; POM1, postoperative month 1; se, standard error.
injection of low dose TA is reported to have minimal effect 
on IOP in eyes with no history of glaucoma or steroid-induced 
ocular hypertension.8 We found no significant rise in 
postoperative IOP in dexamethasone-treated glaucomatous 
eyes compared to control. However five (11.6%) treated 
glaucomatous eyes did develop IOP elevation two to seven 
weeks after PE, all of which returned to baseline IOP after 
discontinuation of topical steroids and addition of original 
antiglaucoma medications. While simultaneous treatment 
with topical corticosteroids almost certainly contributed to 
this rise in IOP, adjunct intracameral dexamethasone should 
be used with some caution in patients known to be steroid 
responders.
There are several limitations in this study that should 
be considered. First are the innate pitfalls of a retrospective 
chart review in which variables are not strictly controlled 
and occasionally a variable may be missing from the medical 
record. The academic training environment also introduces 
bias from variability in clinicians and their preferences in 
medication regimen, including the course of postoperative 
topical corticosteroids. We expect minimal selection bias 
because eyes were treated with dexamethasone in a con-
secutive manner, reflecting a change in surgical practice. It 
would have been beneficial if variables were graded more 
precisely rather than in the binary manner often used in this 
investigation. Since this study involved primarily glaucoma-
tous eyes with varying degrees of visual field defects, it was 
impossible to accurately assess VA change in the immediate 
postoperative period. Furthermore, the experimental groups, 
especially the combined surgeries were limited by small 
sample size and insufficient power. Our statistical analyses 
did not account for the use of fellow eyes as dependent data 
points, or for ethnic background which may influence the 
prevalence of open angle glaucoma and tendency toward 
postoperative inflammation. Lastly, the length of follow-up 
may have been inadequate to identify all cases of CME and 
PCO which may present up to three months and five years 
after cataract surgery, respectively.30,31
Future studies will benefit from a large-scale blinded 
prospective experimental design, strictly defined grading 
criteria, pre- and postoperative office visits at regular 
time intervals, and better control of variables such as 
postoperative medication regimens. It will be useful to 
compare the outcomes of intracameral dexamethasone with 
other routes of delivery such as subconjunctival injection, 
and with other types of steroids such as TA. It also remains 
to be determined if a single postoperative injection of 
intracameral dexamethasone can replace the use of topical 
steroids altogether. The glaucomatous and uveitic eye 
populations would be of interest for further investigations 
because these eyes are particularly prone to a variety 
of complications from poorly-controlled postoperative 
inflammation. It will also be useful to study the effect of 
intracameral dexamethasone after other types of ocular 
surgery in glaucomatous eyes such as trabeculectomy 
and canaloplasty. The safety of dexamethasone requires 
further examination, especially in eyes known to be steroid 
responders.
In conclusion, this study demonstrates that intracameral 
dexamethasone given at the end of cataract surgery safely 
and significantly reduces postoperative inflammatory AC 
cells in glaucomatous and nonglaucomatous eyes, and 
improves subjective reports of recovery in nonglaucomatous 
eyes. We found that dexamethasone did not increase the 
risk of IOP elevation or other complications in eyes with 
or without glaucoma, even in those with a prior history of 
steroid-induced ocular hypertension.
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